Doximity, Inc. (NYSE:DOCS) Stock Has Consensus Price Target of $31.95 According to Brokerages

Posted by Brenda Bartman on Oct 15th, 2026

Shares of Doximity, Inc. (NYSE:DOCS – Get Free Report) have been given a consensus recommendation of “Hold” by the twenty-five ratings firms that are covering the firm, MarketBeat reports. Three research analysts have rated the stock with a sell rating, fourteen have assigned a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company. The average 1-year target price among analysts that have issued a report on the stock in the last year is $31.95.

DOCS has been the topic of a number of recent research reports. Weiss Ratings upgraded shares of Doximity from a “hold (c-)” rating to a “hold (c)” rating in a research report on Tuesday, October 6th. Evercore set a $35.00 price target on shares of Doximity in a research note on Tuesday, September 29th. Wolfe Research upgraded shares of Doximity to an “outperform” rating in a report on Thursday, August 13th. BMO Capital Markets restated a “market perform” rating and issued a $30.00 price objective on shares of Doximity in a report on Friday, August 7th. Finally, Bank of America reaffirmed an “underperform” rating and issued a $20.00 price objective (down from $38.00) on shares of Doximity in a research note on Monday, June 29th.

Check Out Our Latest Analysis on Doximity

Insider Buying and Selling

In other Doximity news, CAO Siddharth Sitaram sold 2,077 shares of the business’s stock in a transaction that occurred on Tuesday, September 15th. The stock was sold at an average price of $26.02, for a total value of $54,043.54. Following the completion of the sale, the chief accounting officer owned 96,045 shares in the company, valued at approximately $2,499,090.90. The trade was a 2.12% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Kira Wampler sold 2,000 shares of the business’s stock in a transaction that occurred on Thursday, October 1st. The shares were sold at an average price of $28.91, for a total value of $57,820.00. Following the completion of the sale, the director owned 27,923 shares of the company’s stock, valued at $807,253.93. The trade was a 6.68% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 16,637 shares of company stock valued at $533,688 over the last quarter. Company insiders own 31.80% of the company’s stock.

Institutional Investors Weigh In On Doximity

Several institutional investors have recently added to or reduced their stakes in DOCS. Fortitude Family Office LLC boosted its holdings in shares of Doximity by 31,271.4% during the third quarter. Fortitude Family Office LLC now owns 2,196 shares of the company’s stock worth $62,000 after purchasing an additional 2,189 shares during the period. Krilogy Financial LLC purchased a new stake in Doximity in the 3rd quarter worth approximately $220,000. Sax Wealth Advisors LLC purchased a new stake in Doximity in the 3rd quarter worth approximately $205,000. GAMMA Investing LLC grew its position in shares of Doximity by 19.8% in the 3rd quarter. GAMMA Investing LLC now owns 5,834 shares of the company’s stock worth $165,000 after buying an additional 963 shares during the last quarter. Finally, Farther Finance Advisors LLC increased its position in Doximity by 265.4% during the 3rd quarter. Farther Finance Advisors LLC now owns 7,180 shares of the company’s stock valued at $203,000 after purchasing an additional 5,215 shares during the period. Hedge funds and other institutional investors own 87.19% of the company’s stock.

Doximity Stock Down 1.9%

Shares of DOCS stock opened at $29.97 on Monday. The business has a 50-day moving average price of $26.46 and a two-hundred day moving average price of $23.52. Doximity has a 12-month low of $17.15 and a 12-month high of $71.37. The firm has a market cap of $5.34 billion, a P/E ratio of 33.57, a price-to-earnings-growth ratio of 23.89 and a beta of 1.22.

Doximity (NYSE:DOCS – Get Free Report) last posted its quarterly earnings data on Thursday, August 6th. The company reported $0.29 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.16 by $0.13. The firm had revenue of $156.62 million during the quarter. Doximity had a return on equity of 18.06% and a net margin of 25.48%. Doximity’s revenue for the quarter was up 7.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.36 earnings per share. As a group, research analysts expect that Doximity will post 0.74 EPS for the current fiscal year.

Doximity News Roundup

Here are the key news stories impacting Doximity this week:

Positive Sentiment: Doximity extended its 13-year partnership with U.S. News & World Report. Doximity will continue powering the Doctor Finder and Patient Connect appointment-booking tools, which are used by more than 65 million Americans annually. The renewal supports the company’s credibility as a healthcare data provider and may help sustain engagement and commercial opportunities. Doximity and U.S. News & World Report Extend Partnership to Connect Patients with Hospitals and Doctors
Neutral Sentiment: Recent coverage also revisited Doximity’s earnings performance and implications for healthcare-focused artificial-intelligence stocks. The company previously exceeded quarterly EPS expectations, but investors appear focused more heavily on questions about the durability and quality of its growth. What Does Doximity Earnings Beat Mean for AI Stocks?
Negative Sentiment: Several firms, including Robbins LLP, Levi & Korsinsky, Kaplan Fox, Rosen Law Firm, DJS Law Group and Pomerantz, promoted the securities class action against Doximity. The complaint covers investors who purchased shares from August 8, 2024, through May 13, 2026, and alleges that Doximity overstated the Newsfeed product’s contribution to revenue growth and misstated its competitive position, including alleged market-share losses. The repeated announcements are likely weighing on DOCS by highlighting potential litigation exposure and renewed scrutiny of management disclosures. Investors have until November 16, 2026, to seek lead-plaintiff status. DOCS Stockholders Have Rights Pomerantz Investor Alert

Doximity Company Profile

(Get Free Report)

Doximity, Inc operates a digital platform designed for U.S. medical professionals. Its network enables physicians, nurse practitioners, physician assistants and other healthcare providers to connect with colleagues, exchange clinical information and access professional resources.

The company offers tools for telehealth and care coordination, including video and phone-based communication services, as well as digital faxing and secure messaging capabilities. Doximity also provides medical news and research content tailored to healthcare professionals.

Doximity generates additional business through recruiting and marketing solutions that help healthcare organizations reach clinicians and promote employment opportunities, services and products.